Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational topical combination therapy, consisting of 1% cannabidiol (CBD) and 10% urea in a lotion form, is being developed by Khon Kaen University in Thailand. It is primarily indicated for the relief of pruritus (itching) and the improvement of skin hydration in patients with systemic sclerosis (scleroderma). Cannabidiol, a non-psychoactive phytocannabinoid derived from *Cannabis sativa*, is thought to exert anti-inflammatory and antipruritic effects by modulating the endocannabinoid system, specifically targeting cannabinoid receptors in the skin. Urea serves as a moisturizing agent and humectant, enhancing skin barrier function and hydration. The formulation is currently being evaluated in a Phase 3 randomized, double-blind, controlled crossover trial to assess its efficacy compared to urea lotion alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on urea + cannabidiol.